Your browser is no longer supported. Please, upgrade your browser.
ADMP Adamis Pharmaceuticals Corporation daily Stock Chart
Adamis Pharmaceuticals Corporation
Index- P/E- EPS (ttm)-0.52 Insider Own1.30% Shs Outstand73.83M Perf Week-14.12%
Market Cap76.13M Forward P/E- EPS next Y-0.15 Insider Trans-8.65% Shs Float72.96M Perf Month12.54%
Income-34.20M PEG- EPS next Q-0.05 Inst Own5.50% Short Float5.28% Perf Quarter-24.44%
Sales20.00M P/S3.81 EPS this Y44.90% Inst Trans-0.32% Short Ratio0.70 Perf Half Y95.08%
Book/sh0.31 P/B2.56 EPS next Y63.40% ROA-73.70% Target Price1.25 Perf Year7.22%
Cash/sh0.08 P/C9.64 EPS next 5Y- ROE-103.20% 52W Range0.27 - 1.51 Perf YTD13.28%
Dividend- P/FCF- EPS past 5Y9.10% ROI-76.90% 52W High-47.46% Beta2.10
Dividend %- Quick Ratio0.80 Sales past 5Y- Gross Margin17.30% 52W Low193.85% ATR0.07
Employees131 Current Ratio1.00 Sales Q/Q-32.80% Oper. Margin- RSI (14)46.61 Volatility7.86% 8.64%
OptionableYes Debt/Eq0.23 EPS Q/Q6.20% Profit Margin- Rel Volume0.29 Prev Close0.81
ShortableYes LT Debt/Eq0.09 Earnings- Payout- Avg Volume5.50M Price0.79
Recom2.70 SMA20-6.11% SMA50-1.18% SMA20019.96% Volume1,572,974 Change-2.36%
May-13-20Upgrade Maxim Group Hold → Buy $1.50
Feb-27-20Downgrade Dawson James Buy → Neutral
Nov-26-19Downgrade Raymond James Outperform → Mkt Perform
Jul-16-19Downgrade B. Riley FBR Neutral → Sell $1.90 → $1.10
Nov-12-18Downgrade B. Riley FBR Buy → Neutral $7.50 → $2.50
May-11-18Reiterated Maxim Group Buy $5 → $10
Mar-23-18Reiterated B. Riley FBR, Inc. Buy $6.25 → $7.50
Dec-05-17Reiterated Maxim Group Buy $13 → $14
Oct-04-17Resumed B. Riley & Co. Buy $9.50
Jul-21-16Reiterated Maxim Group Buy $17 → $10
Dec-01-15Initiated Maxim Group Buy $16
May-29-15Initiated Mizuho Buy $10
Jan-28-14Initiated CRT Capital Buy $15
Oct-12-20 10:24AM  
Sep-18-20 09:00AM  
Sep-17-20 04:05PM  
Sep-16-20 09:23AM  
Sep-03-20 04:05PM  
Aug-25-20 09:00AM  
Aug-21-20 09:00AM  
Aug-17-20 05:55PM  
Aug-14-20 09:00AM  
Aug-06-20 12:30PM  
Aug-05-20 04:05PM  
Jul-23-20 09:00AM  
Jul-01-20 09:00AM  
Jun-18-20 09:00AM  
Jun-15-20 09:00AM  
May-27-20 09:00AM  
May-25-20 10:37AM  
May-18-20 04:35PM  
May-15-20 09:00AM  
May-12-20 08:06AM  
May-11-20 08:35PM  
Apr-29-20 12:00PM  
Apr-23-20 09:00AM  
Apr-21-20 09:00AM  
Apr-15-20 04:05PM  
Apr-01-20 09:00AM  
Mar-30-20 04:40PM  
Feb-21-20 09:15AM  
Feb-19-20 09:00AM  
Jan-03-20 09:31PM  
Dec-23-19 03:59PM  
Dec-19-19 09:00AM  
Nov-27-19 05:09PM  
Nov-25-19 03:16PM  
Nov-18-19 09:00AM  
Nov-12-19 07:05PM  
Nov-07-19 08:54AM  
Nov-06-19 04:05PM  
Nov-05-19 06:53AM  
Nov-04-19 08:00PM  
Nov-01-19 10:30AM  
Oct-18-19 06:26AM  
Oct-08-19 09:00AM  
Oct-01-19 09:00AM  
Sep-26-19 09:00AM  
Sep-12-19 06:20AM  
Sep-03-19 09:00AM  
Aug-28-19 09:00AM  
Aug-26-19 04:05PM  
Aug-19-19 08:48AM  
Aug-14-19 09:00AM  
Aug-08-19 08:40PM  
Aug-07-19 06:38AM  
Aug-05-19 09:00AM  
Aug-02-19 10:30AM  
Aug-01-19 09:00AM  
Jul-31-19 04:05PM  
Jul-26-19 09:13AM  
Jul-25-19 07:37AM  
Jul-24-19 09:00AM  
Jul-18-19 01:52PM  
Jul-09-19 08:30AM  
Jun-27-19 09:00AM  
Jun-20-19 10:02AM  
Jun-11-19 09:00AM  
May-21-19 08:30AM  
May-14-19 09:00AM  
May-13-19 09:06PM  
May-09-19 05:55PM  
May-07-19 09:00AM  
May-02-19 10:32AM  
Mar-15-19 04:39PM  
Mar-14-19 04:55PM  
Mar-13-19 11:51AM  
Feb-27-19 08:13AM  
Feb-26-19 06:54PM  
Feb-20-19 09:00AM  
Jan-23-19 01:51PM  
Jan-17-19 08:06AM  
Jan-16-19 04:48PM  
Jan-03-19 07:30AM  
Jan-02-19 10:21AM  
Dec-31-18 04:02PM  
Dec-28-18 07:46PM  
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hopkins Robert OChief Financial OfficerSep 29Sale0.8020,00016,000274,781Oct 01 06:34 PM
Marguglio David J.SVP and Chief Business OfficerSep 29Sale0.8020,00016,000308,539Oct 01 06:33 PM
Marguglio David J.SVP and Chief Business OfficerAug 18Sale0.878,7497,648328,539Aug 20 05:41 PM
Hopkins Robert OChief Financial OfficerAug 18Sale0.877,4186,484294,781Aug 20 05:38 PM
CARLO DENNIS J PHDPresident & CEOAug 18Sale0.8710,9299,553299,247Aug 20 05:37 PM
Moss Ronald B.Chief Medical OfficerAug 18Sale0.878,7497,648226,373Aug 20 05:36 PM
Daniels Karen K.VP of OperationsAug 18Sale0.875,4804,790140,664Aug 20 05:34 PM
Daniels Karen K.VP of OperationsMay 19Sale0.564,8552,719146,144May 20 04:07 PM
CARLO DENNIS J PHDPresident & CEOMay 18Sale0.569,9135,552310,176May 20 04:06 PM
Hopkins Robert OChief Financial OfficerMay 18Sale0.566,5323,659302,199May 20 04:10 PM
Marguglio David J.SVP and Chief Business OfficerMay 18Sale0.567,7344,332337,288May 20 04:09 PM
Moss Ronald B.Chief Medical OfficerMay 18Sale0.567,7364,333235,122May 20 04:08 PM
Moss Ronald B.Chief Medical OfficerMar 18Sale0.3410,3373,479242,858Mar 19 06:41 PM
Marguglio David J.SVP and Chief Business OfficerMar 18Sale0.3410,3373,479325,022Mar 19 06:40 PM
Hopkins Robert OChief Financial OfficerMar 18Sale0.348,7492,945308,731Mar 19 06:39 PM
Daniels Karen K.VP of OperationsMar 18Sale0.346,4612,175150,999Mar 19 06:36 PM
CARLO DENNIS J PHDPresident & CEOMar 18Sale0.3410,6453,583320,089Mar 19 06:35 PM
CARLO DENNIS J PHDPresident & CEOFeb 24Sale0.6012,4367,505330,734Feb 26 06:34 PM
Marguglio David J.SVP and Chief Business OfficerFeb 24Sale0.609,9486,004335,359Feb 26 06:01 PM
Hopkins Robert OChief Financial OfficerFeb 24Sale0.608,4205,081317,480Feb 26 06:00 PM
Daniels Karen K.VP of OperationsFeb 24Sale0.606,2293,759157,460Feb 26 05:59 PM
Moss Ronald B.Chief Medical OfficerFeb 24Sale0.066,229396253,195Feb 26 05:58 PM
Daniels Karen K.VP of OperationsNov 18Sale0.835,4214,499163,689Nov 20 05:48 PM
Marguglio David J.SVP and Chief Business OfficerNov 18Sale0.878,2837,197365,307Nov 20 05:47 PM
CARLO DENNIS J PHDPresident & CEONov 18Sale0.8410,7608,999343,170Nov 20 05:44 PM
Hopkins Robert OChief Financial OfficerNov 18Sale0.837,3476,099325,900Nov 20 05:50 PM
Moss Ronald B.Chief Medical OfficerNov 18Sale0.858,4487,198259,424Nov 20 05:49 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.